[go: up one dir, main page]

NO20055390L - Thorium-227 for anvendelse i radioterapi pa mykvevssykdommer - Google Patents

Thorium-227 for anvendelse i radioterapi pa mykvevssykdommer

Info

Publication number
NO20055390L
NO20055390L NO20055390A NO20055390A NO20055390L NO 20055390 L NO20055390 L NO 20055390L NO 20055390 A NO20055390 A NO 20055390A NO 20055390 A NO20055390 A NO 20055390A NO 20055390 L NO20055390 L NO 20055390L
Authority
NO
Norway
Prior art keywords
thorium
soft tissue
radiotherapy
tissue diseases
subject
Prior art date
Application number
NO20055390A
Other languages
English (en)
Other versions
NO20055390D0 (no
NO332931B1 (no
Inventor
Roy Larsen
Oyvind Bruland
Original Assignee
Algeta As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0308731.9A external-priority patent/GB0308731D0/en
Application filed by Algeta As filed Critical Algeta As
Publication of NO20055390D0 publication Critical patent/NO20055390D0/no
Publication of NO20055390L publication Critical patent/NO20055390L/no
Publication of NO332931B1 publication Critical patent/NO332931B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Radiology & Medical Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Radiation-Therapy Devices (AREA)
  • Medicinal Preparation (AREA)

Abstract

Derme oppfirmelse tilveiebringer en fremgangsmåte for behandling av mykvevssykdommer i pattedyrsubjektet (et humant eller hundesubjekt), hvor fremgangsmåten omfatter å adminisfrere til subjektet en terapeutisk effektiv mengde av et mykvevsmålrettet kompleks fra thorium-227 og et komplekseringsmiddel, hvor mengden er slik at den aksepterbare ikke-myelotoksiske mengde av radium-223 genereres in vivo ved kjemenedbrytning av det adminisfrerte thorium-227.
NO20055390A 2003-04-15 2005-11-15 Anvendelse av kompleks av thorium-227 og komplekseringsmiddel i fremstilling av et medikament, farmasoytisk sammensetning omfattende mykvevsmalrettingskompleks, mykvevsmalrettingskompleks, fremgangsmate for a danne et kompleks samt sett for bruk i anvendelsen. NO332931B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0308731.9A GB0308731D0 (en) 2003-04-15 2003-04-15 Method of radiotherapy
PCT/GB2004/001654 WO2004091668A1 (en) 2003-04-15 2004-04-15 Thorium-227 for use in radiotherapy of soft tissue disease

Publications (3)

Publication Number Publication Date
NO20055390D0 NO20055390D0 (no) 2005-11-15
NO20055390L true NO20055390L (no) 2006-01-16
NO332931B1 NO332931B1 (no) 2013-02-04

Family

ID=35385222

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20055390A NO332931B1 (no) 2003-04-15 2005-11-15 Anvendelse av kompleks av thorium-227 og komplekseringsmiddel i fremstilling av et medikament, farmasoytisk sammensetning omfattende mykvevsmalrettingskompleks, mykvevsmalrettingskompleks, fremgangsmate for a danne et kompleks samt sett for bruk i anvendelsen.

Country Status (18)

Country Link
EP (1) EP1617876B1 (no)
JP (2) JP5006032B2 (no)
KR (2) KR20060015507A (no)
CN (1) CN100586484C (no)
AU (1) AU2004229218B2 (no)
BR (1) BRPI0409387B8 (no)
CA (1) CA2522148C (no)
CY (1) CY1115407T1 (no)
DK (1) DK1617876T3 (no)
EA (1) EA008195B1 (no)
ES (1) ES2486845T3 (no)
IL (1) IL171148A (no)
MX (1) MXPA05010804A (no)
NO (1) NO332931B1 (no)
NZ (3) NZ606996A (no)
PL (1) PL1617876T3 (no)
PT (1) PT1617876E (no)
ZA (1) ZA200507983B (no)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100586484C (zh) * 2003-04-15 2010-02-03 艾尔格塔公司 用于放射治疗软组织疾病的钍-227
GB201002508D0 (en) * 2010-02-12 2010-03-31 Algeta As Product
GB201007354D0 (en) * 2010-04-30 2010-06-16 Algeta Asa Method
GB201105298D0 (en) * 2011-03-29 2011-05-11 Algeta Asa Pharmaceutical preparation
GB201600154D0 (en) * 2016-01-05 2016-02-17 Bayer As Isotope preparation method
GB201600153D0 (en) * 2016-01-05 2016-02-17 Bayer As Isotope preparation method
EP3554257B1 (en) 2016-12-15 2023-07-12 Société des Produits Nestlé S.A. Compositions and methods that modulate white blood cells or neutrophils in a companion animal
FR3088769B1 (fr) * 2018-11-15 2020-12-25 Orano Med Procede de preparation d'au moins un generateur a haute teneur en radium-228
RU2767567C1 (ru) * 2020-10-27 2022-03-17 Станислав Анатольевич Дороватовский Комплексные соединения, содержащие в своем составе радионуклид 227Th, а также бисфосфонатный фрагмент, способы их получения, а также потенциальное применение в качестве действующего вещества в составе остеотропного радиофармацевтического лекарственного препарата

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0429624T3 (da) * 1989-06-19 1994-05-30 Akzo Nobel Nv Radioimmunterapi under anvendelse af alfa-partikelemission
JPH07505886A (ja) * 1992-04-13 1995-06-29 ザ　ダウ　ケミカル　カンパニー マクロ環状キレート化剤の製造方法及びキレートの形成並びにその結合体
CN1073860C (zh) * 1998-08-20 2001-10-31 中国核动力研究设计院 用于骨肿瘤治疗或诊断的放射性药物药盒的制备方法
MY133346A (en) * 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
NO314537B1 (no) * 1999-12-06 2003-04-07 Anticancer Therapeutic Inv Sa Reseptorbindende konjugater
NO312708B1 (no) * 2000-02-21 2002-06-24 Anticancer Therapeutic Inv Sa Radioaktive liposomer til terapi
AU4906901A (en) * 2000-02-25 2001-09-17 Dangshe Ma Actinium-225 complexes and conjugates for radioimmunotherapy
NO313180B1 (no) * 2000-07-04 2002-08-26 Anticancer Therapeutic Inv Sa Bensökende alfapartikkel emitterende radiofarmasöytika
ITMI20022411A1 (it) * 2002-11-14 2004-05-15 Bracco Imaging Spa Agenti per la diagnosi e la terapia di tumori che espongono sulla superficie delle cellule proteine alterate.
CN100586484C (zh) * 2003-04-15 2010-02-03 艾尔格塔公司 用于放射治疗软组织疾病的钍-227

Also Published As

Publication number Publication date
NZ543044A (en) 2010-04-30
NO20055390D0 (no) 2005-11-15
EA200501456A1 (ru) 2006-06-30
HK1094150A1 (zh) 2007-03-23
NZ606996A (en) 2014-08-29
AU2004229218B2 (en) 2009-05-07
CA2522148C (en) 2010-07-13
ZA200507983B (en) 2007-03-28
EA008195B1 (ru) 2007-04-27
PT1617876E (pt) 2014-08-04
CA2522148A1 (en) 2004-10-28
EP1617876B1 (en) 2014-05-14
KR101274867B1 (ko) 2013-06-13
KR20110022743A (ko) 2011-03-07
JP5006032B2 (ja) 2012-08-22
EP1617876A1 (en) 2006-01-25
CN100586484C (zh) 2010-02-03
JP2006523664A (ja) 2006-10-19
AU2004229218A1 (en) 2004-10-28
IL171148A (en) 2013-12-31
CN1805760A (zh) 2006-07-19
JP5468597B2 (ja) 2014-04-09
MXPA05010804A (es) 2006-03-09
ES2486845T3 (es) 2014-08-19
BRPI0409387A (pt) 2006-04-18
NO332931B1 (no) 2013-02-04
DK1617876T3 (da) 2014-07-21
KR20060015507A (ko) 2006-02-17
CY1115407T1 (el) 2017-01-04
PL1617876T3 (pl) 2015-03-31
BRPI0409387B8 (pt) 2021-05-25
NZ595758A (en) 2013-02-22
JP2012051942A (ja) 2012-03-15
BRPI0409387B1 (pt) 2021-05-11

Similar Documents

Publication Publication Date Title
NO20074999L (no) Metode og preparat for behandling av perifere vaskulaere sykdommer
IL172705A0 (en) Use of [3.2.0] heterocyclic compounds and analogs thereof for the treatment of cancer, inflammation and infectious diseases
MX2022011804A (es) Uso de agentes para el tratamiento de condiciones respiratorias.
NO20070702L (no) Kombinasjonsbehandling for ikke-hematologisk malignitet ved anvendelse av anti-OGF-1R antistoff
MX2010002392A (es) Composiciones de brimonidina mejoradas para tratar eritema.
NZ606825A (en) Methods and compositions for treating complement-associated disorders
MXPA05006940A (es) Formulaciones terapeuticas para el tratamiento de enfermedades relacionadas con beta - amiloide.
TW200806318A (en) Uses of anti-insulin-like growth factor I receptor antibodies
EP2512479A4 (en) METHOD AND COMPOSITIONS FOR TREATING PERIPHERAL VASCULAR DISEASE
ATE375341T1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
MXPA05007857A (es) Moduladores derivados de indol de receptores nucleares de hormonas esteroideas.
ATE355374T1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
EA201270144A1 (ru) Комбинированная терапия при лечении диабета
ATE412646T1 (de) Zur behandlung von schmerzen geeignete therapeutische mittel
IS6558A (is) Blandaðar sjúkdómsmeðferðir með æðaskaðandi virkni
EA200800663A1 (ru) Способ и средство профилактики и лечения нарушенного дыхания во время сна
EA200700214A1 (ru) Мемантин в качестве дополнительной терапии к атипичным антипсихотическим средствам у больных шизофренией
NO20081149L (no) Fremgangsmate for behandling av B-celle-maligniteter ved bruk av TACI-IG fusjonsmolekyl
NO20055390L (no) Thorium-227 for anvendelse i radioterapi pa mykvevssykdommer
EP1677806A4 (en) METHOD FOR THE TREATMENT OF ACUTE AND HYALURONIC ACIDIFICATION CAUSED BY EXCESSIVE INJURY AND STUPIDATION
ATE392219T1 (de) Methoden und medizinische zusammensetzungen zur intravesikalen behandlung von blasenkrebs
MY134562A (en) Methods and compositions to treat conditions associated with neovascularization
DE602005010213D1 (de) Verfahren zur behandlung und diagnose von atemstörungen im schlaf mit zonisamid und mittel zur durchführung des verfahrens
BR0310061A (pt) Métodos para o tratamento de doenças e condições respiratórias com um inibidor seletivo da inos e um inibidor da pde e suas composições
DE602004024221D1 (de) Behandlung von entzündlichen darmerkrankungen mit 2-methylen-19-nor-vitamin d verbindungen